AHS Cancer Control Alberta

🇨🇦Canada
Ownership
Private
Employees
-
Market Cap
-
Website
Clinical Trials
Related News

Loratadine for the Prevention of G-CSF-related Bone Pain

Phase 2
Not yet recruiting
Conditions
Stem Cell Transplant Complications
Interventions
Drug: Placebo
Drug: Loratadine
First Posted Date
2022-06-16
Last Posted Date
2024-06-12
Lead Sponsor
AHS Cancer Control Alberta
Target Recruit Count
78
Registration Number
NCT05421416
Locations
🇨🇦

Cross Cancer Institute, Edmonton, Alberta, Canada

Northern Alberta Linac-MR Image-Guided Radiotherapy (Northern LIGHTs-2)

Phase 1
Recruiting
Conditions
Cancer
Interventions
Device: MR guided radiotherapy
First Posted Date
2022-06-10
Last Posted Date
2024-01-30
Lead Sponsor
AHS Cancer Control Alberta
Target Recruit Count
112
Registration Number
NCT05413473
Locations
🇨🇦

Cross Cancer Institute, Edmonton, Alberta, Canada

Ferric Derisomaltose and Outcomes in the Recovery of Gynecologic Oncology: ERAS (Enhanced Recovery After Surgery)

First Posted Date
2022-06-07
Last Posted Date
2024-02-29
Lead Sponsor
AHS Cancer Control Alberta
Target Recruit Count
82
Registration Number
NCT05407987
Locations
🇨🇦

Tom Baker Cancer Centre, Calgary, Alberta, Canada

Nutritional Supplementation in Head and Neck Cancers

First Posted Date
2022-05-18
Last Posted Date
2024-01-30
Lead Sponsor
AHS Cancer Control Alberta
Target Recruit Count
81
Registration Number
NCT05379712
Locations
🇨🇦

Cross Cancer Institute, Edmonton, Alberta, Canada

A Study Involving Neoadjuvant Chemoradiotherapy with Hypofractionated Radiotherapy in Patients with Esophageal and Gastroesophageal Junction Adenocarcinoma

Not Applicable
Recruiting
Conditions
Esophageal Cancer
Interventions
Radiation: Hypofractionated radiotherapy
First Posted Date
2022-05-11
Last Posted Date
2024-11-18
Lead Sponsor
AHS Cancer Control Alberta
Target Recruit Count
42
Registration Number
NCT05370144
Locations
🇨🇦

Tom Baker Cancer Centre/Arthur J.E. Child Comprehensive Cancer Centre, Calgary, Alberta, Canada

High Heated Humidity in Stem Cell Transplant

Phase 2
Not yet recruiting
Conditions
Autologous Stem Cell Transplant
Interventions
Device: Airvo
First Posted Date
2022-05-03
Last Posted Date
2024-01-30
Lead Sponsor
AHS Cancer Control Alberta
Target Recruit Count
84
Registration Number
NCT05358262
Locations
🇨🇦

Cross Cancer Institute, Edmonton, Alberta, Canada

Steroid Sparing in Immune Related Hepatitis (irH)

Not Applicable
Not yet recruiting
Conditions
Hepatitis Immune
Interventions
Other: Early initiation
Other: Active Surveillance
First Posted Date
2022-04-26
Last Posted Date
2024-03-01
Lead Sponsor
AHS Cancer Control Alberta
Target Recruit Count
55
Registration Number
NCT05345847

Temozolomide Monotherapy or in Combination With Olaparib in Patients With Triple Negative Breast Cancer (TNBC)

Phase 2
Not yet recruiting
Conditions
Breast Cancer Triple Negative
Interventions
Drug: Temozolomide
Drug: Olaparib
First Posted Date
2021-11-22
Last Posted Date
2024-07-30
Lead Sponsor
AHS Cancer Control Alberta
Target Recruit Count
40
Registration Number
NCT05128734
Locations
🇨🇦

Tom Baker Cancer Centre, Calgary, Alberta, Canada

Inguinal Node Sparing Radiotherapy For Patients With Early Stage Anal Cancer

Phase 2
Recruiting
Conditions
Anal Canal Cancer
Interventions
Radiation: chemo-radiation treatment
First Posted Date
2021-09-10
Last Posted Date
2024-08-02
Lead Sponsor
AHS Cancer Control Alberta
Target Recruit Count
45
Registration Number
NCT05040815
Locations
🇨🇦

Cross Cancer Institute, Edmonton, Alberta, Canada

Prognostic Indicators for Radiation-induced Breast Fibrosis

First Posted Date
2021-09-01
Last Posted Date
2024-06-24
Lead Sponsor
AHS Cancer Control Alberta
Target Recruit Count
27
Registration Number
NCT05031065
Locations
🇨🇦

Cross Cancer Institute, Edmonton, Alberta, Canada

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy